Health Sciences Acquisitions Corporation 2 (HSAQ) Closes Orchestra BioMed Deal
by Nicholas Alan Clayton on 2023-01-27 at 10:00am

Health Sciences 2 (NASDAQ:HSAQ) announced that it closed its combination with Orchestra BioMed on January 26.

HSAQ ahead of its vote pre-announced redemption figures of 1,597,888 shares equating to 67.7% redemptions, however, that’s still subject to change.  However, today it was noted that Orchestra BioMed is to receive $70 million in gross proceeds including $20 million from strategic partner Medtronic and additional investments by life sciences fund RTW.

Health Sciences 2 had about $67.7 million in its trust going into the vote after seeing 57.7% of shares redeemed in an earlier extension. Proceeds nonetheless exceeded the the transaction’s $60 million minimum cash condition.

The combined company will commence trading today on the Nasdaq under the symbol “OBIO”. Health Sciences 2 did not include warrants in its units when it IPO’d in August 2020.

The parties announced their $158 million deal with Orchestra BioMed in July 2022. New Hope, Pennsylvania-based Orchestra BioMed develops evidence-based therapeutic solutions for medical procedures that address major medical conditions, with a particular focus on cardiovascular diseases.


  • Jefferies LLC and Piper Sandler & Co. acted as Joint Lead Placement Agents for the Series D Financing
  • Aegis Capital acted as Selling Agent.
  • Jefferies LLC is acting as lead financial advisor and a capital markets advisor to Orchestra BioMed.
  • Piper Sandler & Co. is acting as strategic advisor to Orchestra BioMed
  • Piper Sandler & Co. is acting as a capital markets advisor to Orchestra BioMed.
  • Chardan Capital Markets LLC is serving as financial and capital markets advisor to HSAC2
  • Barclays Capital Inc. is serving as financial and capital markets advisor to HSAC2.
  • Paul Hastings LLP is serving as legal counsel for Orchestra BioMed. Loeb & Loeb LLP is serving as legal counsel for HSAC2.
Recent Posts
by Kristi Marvin on 2024-05-25 at 11:46am

Terms Tracker for the Week Ending May 24, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. It was a bonanza (relatively) of amended and new S-1 filings this week for SPACs. After the parched SPAC desert of April, May has been...

by Nicholas Alan Clayton on 2024-05-24 at 7:59am

At the SPAC of Dawn ‘Tis the season for secondary offerings, or so seems to be the case with recent de-SPACs. Three have announced offerings of shares and warrants over the past 24 hours, perhaps judging the market is more receptive now than in months past even if Thursday saw a late drop. Another potential...

by Nicholas Alan Clayton on 2024-05-23 at 3:58pm

Churchill VII (NYSE:CVII) has upped its enterprise value of target CorpAcq by +10.1% to $1.74 billion from $1.58 billion, according to a refreshed investor presentation released this morning. The new deck also provides some new numbers on CorpAcq’s estimated 2023 results and sheds some light on why Churchill VII may have postponed its May 21...

by Nicholas Alan Clayton on 2024-05-23 at 11:59am

Centurion Acquisition Corp. (NASDAQ:ALFUU) has filed for a $250 million IPO with a commitment by its sponsor group to try and get to its full allotment in-house. The S-1 includes language that “The sponsor limited partners have expressed to us an interest in purchase up to an aggregate of approximately $283,500,000 of the units in this...

by Nicholas Alan Clayton on 2024-05-23 at 7:54am

At the SPAC of Dawn When British regulators adopted new SPAC rules in 2021, it was in part to try and lure more business back to UK exchanges while the SPAC boom was ongoing in the US. Instead, UK-based SPAC volume has remained low and the country’s latest SPAC deal will actually take its target...


Copyright © 2023 SPACInsider, Inc. All Rights Reserved